[3] As in this case, dyspnea on exertion is often the leading clinical symptom; however, dyspnea indicates that the characteristic vascular remodeling of small and middle sized arteries and ...
USA: In patients with advanced pulmonary arterial hypertension (PAH), adding the biologic sotatercept-csrk (Winrevair; Merck) ...